Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 19, Iss. 3, pp. 254-266
Open Access | Times Cited: 808

Showing 1-25 of 808 citing articles:

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 5, pp. 497-530
Closed Access | Times Cited: 1047
First-Line Immunotherapy for Non–Small-Cell Lung Cancer
Martin Reck, Jordi Remón, Matthew D. Hellmann
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 586-597
Closed Access | Times Cited: 564
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Aaron C. Tan, Daniel S.W. Tan
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 611-625
Closed Access | Times Cited: 464
The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 294
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Hamid Mithoowani, Michela Febbraro
Current Oncology (2022) Vol. 29, Iss. 3, pp. 1828-1839
Open Access | Times Cited: 175
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Qing Zhou, Ming Chen, Ou Jiang, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 2, pp. 209-219
Closed Access | Times Cited: 150
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Antonio Passaro, Natasha B. Leighl, Fiona Blackhall, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 466-487
Open Access | Times Cited: 133
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
Mariona Riudavets, Ivana Sullivan, Pamela Abdayem, et al.
ESMO Open (2021) Vol. 6, Iss. 5, pp. 100260-100260
Open Access | Times Cited: 129
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 113
Radon and Lung Cancer: Current Trends and Future Perspectives
Mariona Riudavets, Marta García de Herreros, Benjamin Besse, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3142-3142
Open Access | Times Cited: 111
Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future
Dilara Akhoundova, Mark A. Rubin
Cancer Cell (2022) Vol. 40, Iss. 9, pp. 920-938
Open Access | Times Cited: 86
Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review
Zhicheng Wei, Jing Chen, Fang Zuo, et al.
Journal of Ethnopharmacology (2022) Vol. 300, pp. 115748-115748
Closed Access | Times Cited: 75
Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer
Jeffrey A. Bogart, Saiama N. Waqar, M. Mix
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 661-670
Open Access | Times Cited: 72
Current treatments for non-small cell lung cancer
Qianqian Guo, Liwei Liu, Zelong Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 70
Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions
Haoran Ji, Chuang Hu, Xuhui Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 614-614
Open Access | Times Cited: 45
Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment
Juan Carlos Restrepo, Diana Dueñas, Zuray Corredor, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3474-3474
Open Access | Times Cited: 40
MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma
Jiaqi Liang, Guoshu Bi, Yiwei Huang, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101057-101057
Closed Access | Times Cited: 20
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Yuan Cheng, Tao Zhang, Qing Xu
MedComm (2021) Vol. 2, Iss. 4, pp. 692-729
Open Access | Times Cited: 81
Therapeutic strategies in RET gene rearranged non-small cell lung cancer
Leylah Drusbosky, Estelamari Rodriguez, Richa Dawar, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 73
Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
Yu Wang, Tao Zhang, Yilin Huang, et al.
International Journal of Radiation Oncology*Biology*Physics (2021) Vol. 112, Iss. 5, pp. 1154-1164
Closed Access | Times Cited: 69
PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis
Hongsheng Deng, Yi Zhao, Xiuyu Cai, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 170, pp. 103582-103582
Closed Access | Times Cited: 63
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
Abdoulaye Karaboué, T. Collon, Ida Pavese, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 896-896
Open Access | Times Cited: 63
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer
Xiaomeng Yin, Hu Liao, Yun Hong, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 146-159
Closed Access | Times Cited: 58
Integrative Serum Metabolic Fingerprints Based Multi‐Modal Platforms for Lung Adenocarcinoma Early Detection and Pulmonary Nodule Classification
Lin Wang, Mengji Zhang, Xufeng Pan, et al.
Advanced Science (2022) Vol. 9, Iss. 34
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top